We previously reported the pilot observation of the pallido-nigro-luysian axis-dominant 18F-Florzolotau (a second-generation tau tracer also termed 18F-APN-1607 or 18F-PM-PBB3) uptake in a small cohort of clinically diagnosed patients with PSP [8], indicating the promising clinical utility of this imaging modality. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.